Deltex has published an update on trading for the half-year ended 30 June 2021. While the shock of COVID-19 and its associated hit on levels of elective surgery now appears to be fully reflected in the Group’s share price, the scale of the opportunity that is expected to be presented through international healthcare providers seeking to tackle the huge procedural backlogs that have subsequently built up clearly has not.
Governments and healthcare providers, led by the UK and US, have already committed substantial new investment in an effort to accelerate clearance as soon as they have sufficient evidence regarding the success for their vaccination programmes and improved general availability of ICUs.
This presents Deltex with opportunity for a sharp spike in activity levels to be registered before the end of 2021 and remains its key near-term value driver. Having also continued to advance its next generation product developments/initiatives at a time when both governmental and private payers have become increasingly focused on evidence-based interventions, improved patient outcomes and limited post-operative complications that accrue from adoption of such technologies, the Group appears to have positioned itself to emerge strongly into a post-Pandemic environment.
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to Deltex Medical Group plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2021 Turner Pope Investments (TPI) Limited, all rights reserved.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned